EdgeRock Capital LLC Acquires Shares of 825 Twist Bioscience Co. (NASDAQ:TWST)

EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 825 shares of the company’s stock, valued at approximately $30,000.

Several other institutional investors have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in Twist Bioscience by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company’s stock valued at $16,522,000 after purchasing an additional 5,728 shares during the last quarter. National Bank of Canada FI lifted its holdings in Twist Bioscience by 264,666.7% during the fourth quarter. National Bank of Canada FI now owns 79,430 shares of the company’s stock valued at $2,751,000 after purchasing an additional 79,400 shares during the last quarter. Vestmark Advisory Solutions Inc. purchased a new stake in Twist Bioscience during the fourth quarter valued at about $4,550,000. Los Angeles Capital Management LLC purchased a new stake in Twist Bioscience during the fourth quarter valued at about $321,000. Finally, Victory Capital Management Inc. purchased a new stake in Twist Bioscience during the fourth quarter valued at about $274,000.

Twist Bioscience Price Performance

TWST stock traded down $1.73 during mid-day trading on Wednesday, hitting $41.40. 1,250,117 shares of the stock were exchanged, compared to its average volume of 1,000,721. The business has a fifty day moving average price of $34.18 and a 200 day moving average price of $31.59. Twist Bioscience Co. has a 12 month low of $11.81 and a 12 month high of $44.92. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -12.32 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. During the same quarter in the previous year, the company posted ($1.06) EPS. Twist Bioscience’s quarterly revenue was up 25.1% compared to the same quarter last year. As a group, equities analysts forecast that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Insider Activity

In other news, insider William Banyai sold 798 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the transaction, the insider now directly owns 345,188 shares of the company’s stock, valued at $12,816,830.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the sale, the director now owns 64,169 shares in the company, valued at $2,244,631.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Banyai sold 798 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $29,629.74. Following the completion of the sale, the insider now owns 345,188 shares of the company’s stock, valued at approximately $12,816,830.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,525 shares of company stock valued at $758,272. Corporate insiders own 3.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Evercore ISI raised their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their price target for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Robert W. Baird lifted their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Scotiabank upped their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday. Finally, Barclays lifted their price target on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $42.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.